Careers  |  Sign In  |  Register

Dr. Rotow on the Implications of Next-Generation ALK Inhibitors in NSCLC

Julia Rotow, MD, medical oncologist at Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, reviews new treatment options for non-small cell lung cancer (NSCLC) patients. Dr. Rotow recommends next-generation sequencing to find targeted mutations for ALK-rearranged lung cancer patients. Dr. Rotow also recommends ALK-inhibitors alectinib and brigatinib for patients with limited CNS disease for more systemic control.

Learn more by clicking here.